Danziten (nilotinib) – New drug approval
November 7, 2024 - The FDA approved Azurity Pharmaceuticals’ Danziten (nilotinib) tablets, for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase; chronic phase and accelerated phase Ph+ CML resistant or intolerant to prior therapy that included imatinib.
Top